Solazyme, Inc. Closes Offering of Convertible Senior Subordinated Notes

  Solazyme, Inc. Closes Offering of Convertible Senior Subordinated Notes

     Raises $125 million in Gross Proceeds, Including Exercise in Full of
                            Over-Allotment Option

Business Wire

SOUTH SAN FRANCISCO, Calif. -- January 24, 2013

Solazyme, Inc. (NASDAQ: SZYM) announced today the closing of its offering of
6% Convertible Senior Subordinated Notes due 2018 (the “Notes”) in a private
offering pursuant to Rule 144A under the Securities Act of 1933, as amended.
The issuance of $125 million aggregate principal amount of Notes includes the
exercise in full by Goldman Sachs & Co., sole book-running manager for the
offering, of its option to purchase $10 million aggregate principal amount of
Notes to cover over-allotments.

Solazyme has received aggregate net proceeds from the sale of the Notes of
approximately $119.4 million, after deducting discounts to the initial
purchaser and estimated offering expenses payable by Solazyme. Solazyme
intends to use the net proceeds of the offering to fund project related costs
and capital expenditures and for general corporate purposes.

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor shall it constitute an offer, solicitation
or sale in any jurisdiction in which such offer, solicitation or sale is

About Solazyme, Inc.

Solazyme, Inc. (SZYM) is a renewable oil and bioproducts company that
transforms a range of low-cost plant-based sugars into high-value oils.
Headquartered in South San Francisco, Solazyme’s renewable products can
replace or enhance oils derived from the world’s three existing sources –
petroleum, plants and animal fats. Initially, Solazyme is focused on
commercializing its products into three target markets: (1) fuels and
chemicals, (2) nutrition and (3) skin and personal care.

Solazyme^®, the Solazyme logo and other trademarks or service names are
trademarks of Solazyme, Inc.

Forward Looking Statements

This press release includes forward-looking statements regarding Solazyme’s
financing plans, including statements related to Solazyme’s intended use of
the net proceeds from the sale of the Notes. Such statements are subject to
certain risks and uncertainties including, without limitation, risks related
to market and other general economic conditions and the anticipated use of the
net proceeds from the sale of the Notes. Solazyme’s forward-looking statements
also involve assumptions that, if they never materialize or prove correct,
could cause its results to differ materially from those expressed or implied
by such forward-looking statements. Although Solazyme’s forward-looking
statements reflect the good faith judgment of its management, these statements
are based only on facts and factors currently known by Solazyme. As a result,
you are cautioned not to rely on these forward-looking statements.


Solazyme, Inc.
Genet Garamendi
Corporate Communications
Brainerd Communicators, Inc.
Jeff Majtyka, 212-986-6667
Mike Smargiassi, 212-986-6667
Press spacebar to pause and continue. Press esc to stop.